ID   PC-7/CPT
AC   CVCL_A787
DR   cancercelllines; CVCL_A787
DR   Wikidata; Q54938466
RX   PubMed=1332703;
RX   PubMed=2168285;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; CPT-11).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Gly719Ser (c.2155G>A); ClinVar=VCV000016612; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Thr729Ala (c.2185G>A); Zygosity=Unspecified (PubMed=1332703).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A786 ! PC-7
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 15
//
RX   PubMed=1332703; DOI=10.1016/0006-291X(92)91094-7;
RA   Kubota N., Kanzawa F., Nishio K., Takeda Y., Ohmori T., Fujiwara Y.,
RA   Terashima Y., Saijo N.;
RT   "Detection of topoisomerase I gene point mutation in CPT-11 resistant
RT   lung cancer cell line.";
RL   Biochem. Biophys. Res. Commun. 188:571-577(1992).
//
RX   PubMed=2168285;
RA   Kanzawa F., Sugimoto Y., Minato K., Kasahara K., Bungo M.,
RA   Nakagawa K., Fujiwara Y., Liu L.F., Saijo N.;
RT   "Establishment of a camptothecin analogue (CPT-11)-resistant cell line
RT   of human non-small cell lung cancer: characterization and mechanism of
RT   resistance.";
RL   Cancer Res. 50:5919-5924(1990).
//